Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Next Previous
Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegipanermin (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MINDFuL
  • Sponsors INmune Bio

Most Recent Events

  • 19 Mar 2026 According to an INmune Bio media release, data from this trial presented at AD/PD 2026 taking place March 17-21, 2026 in Copenhagen, Denmark.
  • 23 Feb 2026 According to an INmune Bio media release, the company will will host a webinar focused on the registrational pathway of XPro1595 for the treatment of early Alzheimers disease on February 27, 2026 at 9:30 a.m. ET, including detailed presentation of MINDFuL Trial Results and Path to the FDA End-of-Phase 2 Meeting,Registrational Study Design and FDA Feedback and Path to Phase 3 and Maximizing XPro Potential Through Global Partnership and strategic roadmap.
  • 23 Feb 2026 According to an INmune Bio media release, Post the completion of this trial, along with feedback from the FDA in a recent End-Of-Phase 2 meeting, the Company has received alignment supporting advancement to a registrational study in patients with Alzheimers Disease with biomarkers of Inflammation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top